← All trials
NCT05135650
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2022
- Primary completion
- Jan 15, 2023
- Completion date
- Jan 15, 2023
- First posted
- Nov 26, 2021
- Last posted
- Nov 26, 2021
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- National Marrow Donor ProgramCollaborator
- University of WashingtonOverall official - principal investigator
- Vir Biotechnology, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.